NASDAQ:ICLR - Icon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$136.75 +0.08 (+0.06 %)
(As of 03/21/2019 04:00 PM ET)
Previous Close$136.67
Today's Range$135.30 - $137.74
52-Week Range$110.21 - $155.33
Volume250,563 shs
Average Volume335,408 shs
Market Capitalization$7.38 billion
P/E Ratio21.74
Dividend YieldN/A
Beta0.66
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$7.7086 per share
Book Value$25.09 per share

Profitability

Net Income$322.66 million

Miscellaneous

Employees13,250
Market Cap$7.38 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) released its quarterly earnings results on Wednesday, February, 20th. The medical research company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.60 by $0.02. The medical research company earned $679.03 million during the quarter, compared to analyst estimates of $675.04 million. Icon had a net margin of 12.43% and a return on equity of 26.01%. The company's quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.43 earnings per share. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon issued an update on its FY19 earnings guidance on Wednesday, February, 20th. The company provided earnings per share (EPS) guidance of $6.69-6.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.81. The company issued revenue guidance of $2.735 - $2.835 billion, compared to the consensus revenue estimate of $2.78 billion.

What price target have analysts set for ICLR?

10 analysts have issued 12-month price targets for Icon's stock. Their forecasts range from $136.00 to $168.00. On average, they expect Icon's stock price to reach $152.3333 in the next year. This suggests a possible upside of 11.4% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

Media coverage about ICLR stock has been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Icon earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the near future.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), Procter & Gamble (PG), NVIDIA (NVDA), Mastercard (MA), Amgen (AMGN), Micron Technology (MU), Johnson & Johnson (JNJ), Visa (V) and Cisco Systems (CSCO).

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include WCM Investment Management LLC (9.75%), Acadian Asset Management LLC (4.00%), Pendal Group Ltd (2.60%), Boston Partners (2.55%), FMR LLC (2.18%) and Massachusetts Financial Services Co. MA (2.09%).

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Boston Partners, Mckinley Capital Management LLC Delaware, Chiron Investment Management LLC, Bank of America Corp DE, Lord Abbett & CO. LLC and Globeflex Capital L P.

Which major investors are buying Icon stock?

ICLR stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Norges Bank, WCM Investment Management LLC, State of Tennessee Treasury Department, American Century Companies Inc., Blackcrane Capital LLC, Comgest Global Investors S.A.S. and Massachusetts Financial Services Co. MA.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $136.75.

How big of a company is Icon?

Icon has a market capitalization of $7.38 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,250 workers across the globe.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  446 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  790
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel